103
66.
TatoulisJ,BuxtonBF,FullerJA.Patenciesof2127arterialtocoronaryconduitsover 15 years. Ann Thorac
Surg 2004;77(1):93–101.
67.
Hattler B,
Messenger JC, Shroyer AL,
Collins JF, Haugen SJ,
Garcia JA, Baltz JH, Cleveland JC Jr.,
Novitzky D, Grover FL. Off-Pump coronary artery bypass surgery is associated with worse arterial
and saphenous vein graft patency and less effective revascularization: Results from the Veterans
Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation 2012;125(23):2827–2835.
68.
AlexanderJH,HafleyG,HarringtonRA,PetersonED,FergusonTBJr.,LorenzTJ, Goyal A, Gibson M,
Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an E2F
transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft
surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294(19):2446–2454.
69.
Tatoulis J, Buxton BF, Fuller JA. The right internal thoracic artery: the forgotten conduit:5,766
patients and 991 angiograms. Ann Thorac Surg 2011;92(1):9 – 15; dis- cussion 15–17.
70.
Yap CH, Sposato L, Akowuah E, Theodore S, Dinh DT, Shardey GC, Skillington PD, Tatoulis J, Yii
M, Smith JA, Mohajeri M, Pick A, Seevanayagam S, Reid CM. Contemporary results show repeat
coronary artery bypass grafting remains a risk factor for operative mortality. Ann Thorac Surg
2009;87(5):1386 – 1391.
71.
Harskamp RE, Beijk MA, Damman P, Kuijt WJ, Woudstra P, Grundeken MJ, Kloek JJ, Tijssen JG,
de Mol BA, de Winter RJ. Clinical outcome after surgical or percutaneous revascularization in
coronary bypass graft failure. J Cardiovasc Med (Hagers- town) 2013;14(6):438 – 445.
72.
Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, Jonas M, Popma JJ, Pavliska J, Wahr D,
Rogers C. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using
the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am
Coll Cardiol 2007;50(15):1442 – 1449.
73.
Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents vs. bare- metal stents in
saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv
2010;3(12):1262 – 1273.
74.
Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen
D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas
P, Berger P, Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent
implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of
Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011;4(2):176 – 182.
75.
Alam M, Bandeali SJ, Virani SS, Jneid HM, Shahzad SA, Ramanathan KB, Kar B, Kleiman NS,
Lakkis N. Clinical outcomes of percutaneous interventions in saphenous vein grafts using drug-
eluting stents compared to bare-metal stents: a comprehensive meta-analysisof all randomized clinical
trials. Clin Cardiol 2012;35(5): 291 – 296.
76.
Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD. Outcomes
after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from
the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. JACC
Cardiovasc Interv 2010;3(7):742 – 750.
77.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ,
Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM.
Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357(20):2001 – 2015.
78.
Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner
CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S, Investigators C-O. Dose comparisons of
clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930 – 942.
79.
Shen L, Hu S, Wang H, Xiong H, Zheng Z, Li L, Xu B, Yan H, Gao R. One-stop hybrid coronary
revascularization vs. coronary artery bypass grafting and percutaneous coronary intervention for the
104
treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution. J
Am Coll Cardiol 2013;61(25): 2525 – 2533.
80.
Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ, Exner DV. Prior coronary artery bypass
surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation
2001;104(13):1489 – 1493.
81.
Jakobsen CJ, Ryhammer PK, Tang M, Andreasen JJ, Mortensen PE. Transfusion of blood during
cardiac surgery is associated with higher long-term mortality in low-risk patients. Eur J Cardiothorac
Surg 2012;42(1):114 – 120.
82.
Zenati MA, Shroyer AL, Collins JF, Hattler B, Ota T, Almassi GH, Amidi M, Novitzky D, Grover
FL, Sonel AF. Impact of endoscopic vs. open saphenous vein harvest technique on late coronary artery
bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. J Thorac
Cardiovasc Surg 2011; 141(2):338 – 344.
83.
Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, Gibson
CM, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Endoscopic vs. Open Vein-Graft
Harvesting in Coronary-Artery Bypass Surgery. N Eng J Med 2009;361(3):235–244.
84.
Lytle BW. Skeletonized internal thoracic artery grafts and wound complications. J Thorac Cardiovasc
Surg 2001;121(4):625 – 627.
85.
Taggart DP. Incomplete revascularization: appropriate and inappropriate. Eur J Cardiothorac Surg
2012;41(3):542 – 543.
86.
Zimarino M, Curzen N, Cicchitti V, De Caterina R. The adequacy of myocardial revascularization in
patients with multivessel coronary artery disease. Int J Cardiol 2013;168(3):1748 – 1757.
87.
Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft surgery vs.
percutaneous coronary intervention. Circulation 2006;114(3):249 – 255.
88.
Farooq V, Serruys PW, Garcia – Garcia HM, Zhang Y, Bourantas CV, Holmes DR, Mack M, Feldman
T, Morice MC, Stahle E, James S,
Colombo A, Diletti R, Papafaklis MI, de Vries T, Morel MA, van
Es GA, Mohr FW, Dawkins KD, Kappetein AP, Sianos G, Boersma E. The negative impact of
incomplete angiographic revascularization on clinical outcomes and its association with total
occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with
Taxus and
Cardiac Surgery) trial. J Am Coll Cardiol 2013;61(3):282–294.
89.
Head SJ, Mack MJ, Holmes DR Jr., Mohr FW, Morice MC, Serruys PW, Kappetein AP. Incidence,
predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and
coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac
Surg 2012;41(3):
535 – 541.
90.
Kim YH, Park DW, Lee JY, Kim WJ, Yun SC, Ahn JM, Song HG, Oh JH, Park JS,
Kang SJ, Lee
SW, Lee CW, Park SW, Park SJ. Impact of angiographic complete revascularization after drug-eluting
stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease.
Circulation 2011;123(21): 2373 – 2381.
91.
MohammadiS,KalavrouziotisD,DagenaisF,VoisineP,CharbonneauE.Completeness
of
revascularization and survival among octogenarians with triple-vessel disease. Ann Thorac Surg
2012;93(5):1432–1437.
92.
YiG,YounYN,JooHC,HongS,YooKJ.Associationofincompleterevascularization
with
long-term
survival after off-pump coronary artery bypass grafting. J Surg Res 2013;185(1):166–173.
93.
.RastanAJ,WaltherT,FalkV,KempfertJ,MerkD,LehmannS,HolzheyD,MohrFW. Does reasonable
incomplete surgical revascularization affect early or long-term survival in patients with multivessel
coronary artery disease receiving left internal mammary artery bypass to left anterior descending
artery? Circulation 2009; 120(11 Suppl):S70–77.
94.
Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D, Brilakis ES. Outcomes